JP4118565B2 - デカヒドロ−イソキノリン - Google Patents

デカヒドロ−イソキノリン Download PDF

Info

Publication number
JP4118565B2
JP4118565B2 JP2001568934A JP2001568934A JP4118565B2 JP 4118565 B2 JP4118565 B2 JP 4118565B2 JP 2001568934 A JP2001568934 A JP 2001568934A JP 2001568934 A JP2001568934 A JP 2001568934A JP 4118565 B2 JP4118565 B2 JP 4118565B2
Authority
JP
Japan
Prior art keywords
decahydro
methyl
methanone
piperazin
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001568934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528096A5 (enExample
JP2003528096A (ja
Inventor
トーマス・ヨット・トロクスラー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2003528096A publication Critical patent/JP2003528096A/ja
Publication of JP2003528096A5 publication Critical patent/JP2003528096A5/ja
Application granted granted Critical
Publication of JP4118565B2 publication Critical patent/JP4118565B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2001568934A 2000-03-23 2001-03-21 デカヒドロ−イソキノリン Expired - Fee Related JP4118565B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007108.4 2000-03-23
GBGB0007108.4A GB0007108D0 (en) 2000-03-23 2000-03-23 Organic compounds
PCT/EP2001/003211 WO2001070731A1 (en) 2000-03-23 2001-03-21 Decahydro-isoquinolines

Publications (3)

Publication Number Publication Date
JP2003528096A JP2003528096A (ja) 2003-09-24
JP2003528096A5 JP2003528096A5 (enExample) 2007-12-27
JP4118565B2 true JP4118565B2 (ja) 2008-07-16

Family

ID=9888307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568934A Expired - Fee Related JP4118565B2 (ja) 2000-03-23 2001-03-21 デカヒドロ−イソキノリン

Country Status (15)

Country Link
US (1) US6635647B2 (enExample)
EP (1) EP1268466B1 (enExample)
JP (1) JP4118565B2 (enExample)
AR (1) AR029821A1 (enExample)
AT (1) ATE298332T1 (enExample)
AU (1) AU2001239310A1 (enExample)
CA (1) CA2402751C (enExample)
CO (1) CO5271675A1 (enExample)
DE (1) DE60111621T2 (enExample)
DK (1) DK1268466T3 (enExample)
ES (1) ES2243462T3 (enExample)
GB (1) GB0007108D0 (enExample)
PE (1) PE20011114A1 (enExample)
PT (1) PT1268466E (enExample)
WO (1) WO2001070731A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2641120A1 (en) * 2006-01-30 2007-08-02 Speedel Experimenta Ag Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329389B1 (en) * 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use

Also Published As

Publication number Publication date
DK1268466T3 (da) 2005-10-10
EP1268466A1 (en) 2003-01-02
DE60111621T2 (de) 2006-05-18
DE60111621D1 (de) 2005-07-28
GB0007108D0 (en) 2000-05-17
AR029821A1 (es) 2003-07-16
US6635647B2 (en) 2003-10-21
PE20011114A1 (es) 2001-11-30
JP2003528096A (ja) 2003-09-24
CA2402751C (en) 2010-01-19
AU2001239310A1 (en) 2001-10-03
US20030120072A1 (en) 2003-06-26
EP1268466B1 (en) 2005-06-22
CA2402751A1 (en) 2001-09-27
ATE298332T1 (de) 2005-07-15
CO5271675A1 (es) 2003-04-30
ES2243462T3 (es) 2005-12-01
PT1268466E (pt) 2005-10-31
WO2001070731A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
JP2003528096A (ja) デカヒドロ−イソキノリン
JP7095106B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
JP7476100B2 (ja) ピリダジノン誘導体
CA2806324C (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
ES2782376T3 (es) Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
CN104936945B (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
KR101800595B1 (ko) 자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체
WO2022187688A1 (en) Covalent kras-binding compounds for therapeutic purposes
BR112018015283B1 (pt) Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central
CN1795194A (zh) 新的吡啶并吡嗪类化合物及其用作激酶抑制剂的用途
CN104936944B (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
CN107880038B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
WO2022073470A1 (zh) 杂环取代的稠合γ-咔啉类衍生物、其制备方法、中间体及应用
JP7688242B1 (ja) ３－フェニルプロピルアミン誘導体
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
WO2021149767A1 (ja) ヘテロ環誘導体
CN101054380B (zh) 用作细胞周期依赖性蛋白激酶抑制剂的吡唑并嘧啶类衍生物
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
WO2021039961A1 (ja) 縮環ピラゾール誘導体
US20080167319A1 (en) 7-(4-(4-[3-chloro-2-(trifluoromethyl)phenyl]piperazin-1-yl)butoxy)-[1,8]-naphthyridin-2(1h)-one
US20060030566A1 (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
HK40094062A (en) HETEROCYCLIC SUBSTITUTED FUSED γ-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
HK40094062B (en) HETEROCYCLIC SUBSTITUTED FUSED γ-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
CN118852146A (zh) 一种吗啉杂环类化合物的晶型及其制备方法和应用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20051227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070807

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20071106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080423

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110502

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees